nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP4A11—Dexamethasone—multiple sclerosis	0.117	0.169	CbGbCtD
Lansoprazole—CYP1B1—Mitoxantrone—multiple sclerosis	0.0936	0.135	CbGbCtD
Lansoprazole—ABCG2—Cladribine—multiple sclerosis	0.061	0.088	CbGbCtD
Lansoprazole—CYP1B1—Dexamethasone—multiple sclerosis	0.0485	0.07	CbGbCtD
Lansoprazole—ABCG2—Mitoxantrone—multiple sclerosis	0.0445	0.0642	CbGbCtD
Lansoprazole—CYP2D6—Fingolimod—multiple sclerosis	0.0321	0.0464	CbGbCtD
Lansoprazole—ABCG2—Dexamethasone—multiple sclerosis	0.0231	0.0333	CbGbCtD
Lansoprazole—ABCB1—Methylprednisolone—multiple sclerosis	0.022	0.0317	CbGbCtD
Lansoprazole—CYP1A1—Dexamethasone—multiple sclerosis	0.0213	0.0307	CbGbCtD
Lansoprazole—CYP3A4—Fingolimod—multiple sclerosis	0.0204	0.0295	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—multiple sclerosis	0.0185	0.0268	CbGbCtD
Lansoprazole—CYP2C19—Prednisone—multiple sclerosis	0.0165	0.0238	CbGbCtD
Lansoprazole—ABCB1—Mitoxantrone—multiple sclerosis	0.016	0.0231	CbGbCtD
Lansoprazole—ABCB1—Betamethasone—multiple sclerosis	0.0143	0.0206	CbGbCtD
Lansoprazole—ABCB1—Prednisolone—multiple sclerosis	0.0141	0.0204	CbGbCtD
Lansoprazole—ABCB1—Prednisone—multiple sclerosis	0.0133	0.0192	CbGbCtD
Lansoprazole—CYP3A4—Methylprednisolone—multiple sclerosis	0.0132	0.019	CbGbCtD
Lansoprazole—CYP2C8—Dexamethasone—multiple sclerosis	0.0123	0.0177	CbGbCtD
Lansoprazole—CYP2C19—Dexamethasone—multiple sclerosis	0.0103	0.0149	CbGbCtD
Lansoprazole—CYP3A4—Triamcinolone—multiple sclerosis	0.00998	0.0144	CbGbCtD
Lansoprazole—CYP3A4—Mitoxantrone—multiple sclerosis	0.00961	0.0139	CbGbCtD
Lansoprazole—CYP2C9—Dexamethasone—multiple sclerosis	0.00857	0.0124	CbGbCtD
Lansoprazole—CYP3A4—Betamethasone—multiple sclerosis	0.00856	0.0124	CbGbCtD
Lansoprazole—CYP3A4—Prednisolone—multiple sclerosis	0.00845	0.0122	CbGbCtD
Lansoprazole—ABCB1—Dexamethasone—multiple sclerosis	0.00831	0.012	CbGbCtD
Lansoprazole—CYP3A4—Prednisone—multiple sclerosis	0.00798	0.0115	CbGbCtD
Lansoprazole—CYP2D6—Dexamethasone—multiple sclerosis	0.00783	0.0113	CbGbCtD
Lansoprazole—ABCB1—Methotrexate—multiple sclerosis	0.00668	0.00965	CbGbCtD
Lansoprazole—CYP3A4—Dexamethasone—multiple sclerosis	0.00498	0.00719	CbGbCtD
Lansoprazole—MAPT—retina—multiple sclerosis	0.000888	0.121	CbGeAlD
Lansoprazole—MAPT—medulla oblongata—multiple sclerosis	0.000642	0.0877	CbGeAlD
Lansoprazole—MAPT—midbrain—multiple sclerosis	0.000587	0.0802	CbGeAlD
Lansoprazole—MAPT—spinal cord—multiple sclerosis	0.000572	0.0782	CbGeAlD
Lansoprazole—MAPT—cerebellum—multiple sclerosis	0.000454	0.062	CbGeAlD
Lansoprazole—MAPT—brain—multiple sclerosis	0.000369	0.0504	CbGeAlD
Lansoprazole—ATP4A—nervous system—multiple sclerosis	0.000358	0.0489	CbGeAlD
Lansoprazole—ATP4A—central nervous system—multiple sclerosis	0.000345	0.0471	CbGeAlD
Lansoprazole—ATP4A—cerebellum—multiple sclerosis	0.000337	0.0461	CbGeAlD
Lansoprazole—ATP4A—brain—multiple sclerosis	0.000274	0.0374	CbGeAlD
Lansoprazole—CYP1B1—nervous system—multiple sclerosis	0.000143	0.0195	CbGeAlD
Lansoprazole—ABCG2—medulla oblongata—multiple sclerosis	0.000141	0.0193	CbGeAlD
Lansoprazole—CYP2D6—brainstem—multiple sclerosis	0.000139	0.019	CbGeAlD
Lansoprazole—CYP1B1—central nervous system—multiple sclerosis	0.000137	0.0188	CbGeAlD
Lansoprazole—CYP1B1—cerebellum—multiple sclerosis	0.000134	0.0183	CbGeAlD
Lansoprazole—ABCG2—midbrain—multiple sclerosis	0.000129	0.0176	CbGeAlD
Lansoprazole—ABCG2—spinal cord—multiple sclerosis	0.000126	0.0172	CbGeAlD
Lansoprazole—CYP1B1—brain—multiple sclerosis	0.000109	0.0149	CbGeAlD
Lansoprazole—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000103	0.00141	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000102	0.0014	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000102	0.0014	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000101	0.00138	CbGpPWpGaD
Lansoprazole—CYP1A1—nervous system—multiple sclerosis	0.000101	0.0138	CbGeAlD
Lansoprazole—CYP4A11—Metabolism—SRM—multiple sclerosis	0.0001	0.00137	CbGpPWpGaD
Lansoprazole—ABCG2—cerebellum—multiple sclerosis	9.99e-05	0.0137	CbGeAlD
Lansoprazole—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	9.96e-05	0.00136	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	9.91e-05	0.00136	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	9.89e-05	0.00136	CbGpPWpGaD
Lansoprazole—CYP1A1—central nervous system—multiple sclerosis	9.7e-05	0.0133	CbGeAlD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	9.7e-05	0.00133	CbGpPWpGaD
Lansoprazole—ABCB1—retina—multiple sclerosis	9.64e-05	0.0132	CbGeAlD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.63e-05	0.00132	CbGpPWpGaD
Lansoprazole—Nausea—Azathioprine—multiple sclerosis	9.59e-05	0.000423	CcSEcCtD
Lansoprazole—Tachycardia—Methylprednisolone—multiple sclerosis	9.59e-05	0.000423	CcSEcCtD
Lansoprazole—Skin disorder—Methylprednisolone—multiple sclerosis	9.55e-05	0.000421	CcSEcCtD
Lansoprazole—Malnutrition—Prednisone—multiple sclerosis	9.54e-05	0.00042	CcSEcCtD
Lansoprazole—Erythema—Prednisone—multiple sclerosis	9.54e-05	0.00042	CcSEcCtD
Lansoprazole—Hyperhidrosis—Triamcinolone—multiple sclerosis	9.52e-05	0.00042	CcSEcCtD
Lansoprazole—Agranulocytosis—Methotrexate—multiple sclerosis	9.52e-05	0.000419	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methylprednisolone—multiple sclerosis	9.5e-05	0.000419	CcSEcCtD
Lansoprazole—Convulsion—Betamethasone—multiple sclerosis	9.49e-05	0.000418	CcSEcCtD
Lansoprazole—Convulsion—Dexamethasone—multiple sclerosis	9.49e-05	0.000418	CcSEcCtD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	9.48e-05	0.0013	CbGpPWpGaD
Lansoprazole—Hypertension—Dexamethasone—multiple sclerosis	9.45e-05	0.000417	CcSEcCtD
Lansoprazole—Hypertension—Betamethasone—multiple sclerosis	9.45e-05	0.000417	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—MYC—multiple sclerosis	9.43e-05	0.00129	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TGFB1—multiple sclerosis	9.41e-05	0.00129	CbGpPWpGaD
Lansoprazole—Asthenia—Mitoxantrone—multiple sclerosis	9.37e-05	0.000413	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—TNF—multiple sclerosis	9.37e-05	0.00128	CbGpPWpGaD
Lansoprazole—Myalgia—Dexamethasone—multiple sclerosis	9.32e-05	0.000411	CcSEcCtD
Lansoprazole—Myalgia—Betamethasone—multiple sclerosis	9.32e-05	0.000411	CcSEcCtD
Lansoprazole—Anxiety—Betamethasone—multiple sclerosis	9.29e-05	0.000409	CcSEcCtD
Lansoprazole—Anxiety—Dexamethasone—multiple sclerosis	9.29e-05	0.000409	CcSEcCtD
Lansoprazole—CYP4A11—Biological oxidations—POMC—multiple sclerosis	9.27e-05	0.00127	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	9.23e-05	0.00127	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	9.23e-05	0.00127	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—MAPK1—multiple sclerosis	9.22e-05	0.00126	CbGpPWpGaD
Lansoprazole—Discomfort—Dexamethasone—multiple sclerosis	9.21e-05	0.000406	CcSEcCtD
Lansoprazole—Discomfort—Betamethasone—multiple sclerosis	9.21e-05	0.000406	CcSEcCtD
Lansoprazole—Hypotension—Methylprednisolone—multiple sclerosis	9.18e-05	0.000405	CcSEcCtD
Lansoprazole—Pain—Prednisolone—multiple sclerosis	9.16e-05	0.000404	CcSEcCtD
Lansoprazole—Hepatitis—Methotrexate—multiple sclerosis	9.16e-05	0.000403	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	9.1e-05	0.00125	CbGpPWpGaD
Lansoprazole—Pharyngitis—Methotrexate—multiple sclerosis	9.09e-05	0.0004	CcSEcCtD
Lansoprazole—Urinary tract disorder—Methotrexate—multiple sclerosis	9.04e-05	0.000398	CcSEcCtD
Lansoprazole—Vision blurred—Prednisone—multiple sclerosis	8.99e-05	0.000396	CcSEcCtD
Lansoprazole—Urethral disorder—Methotrexate—multiple sclerosis	8.98e-05	0.000395	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	8.97e-05	0.000395	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	8.95e-05	0.000394	CcSEcCtD
Lansoprazole—Anaphylactic shock—Dexamethasone—multiple sclerosis	8.94e-05	0.000394	CcSEcCtD
Lansoprazole—Anaphylactic shock—Betamethasone—multiple sclerosis	8.94e-05	0.000394	CcSEcCtD
Lansoprazole—Oedema—Betamethasone—multiple sclerosis	8.94e-05	0.000394	CcSEcCtD
Lansoprazole—Oedema—Dexamethasone—multiple sclerosis	8.94e-05	0.000394	CcSEcCtD
Lansoprazole—Diarrhoea—Mitoxantrone—multiple sclerosis	8.93e-05	0.000394	CcSEcCtD
Lansoprazole—Insomnia—Triamcinolone—multiple sclerosis	8.91e-05	0.000392	CcSEcCtD
Lansoprazole—Insomnia—Methylprednisolone—multiple sclerosis	8.89e-05	0.000392	CcSEcCtD
Lansoprazole—Infection—Betamethasone—multiple sclerosis	8.88e-05	0.000391	CcSEcCtD
Lansoprazole—Infection—Dexamethasone—multiple sclerosis	8.88e-05	0.000391	CcSEcCtD
Lansoprazole—Ill-defined disorder—Prednisone—multiple sclerosis	8.85e-05	0.00039	CcSEcCtD
Lansoprazole—Paraesthesia—Triamcinolone—multiple sclerosis	8.84e-05	0.00039	CcSEcCtD
Lansoprazole—Feeling abnormal—Prednisolone—multiple sclerosis	8.83e-05	0.000389	CcSEcCtD
Lansoprazole—Paraesthesia—Methylprednisolone—multiple sclerosis	8.83e-05	0.000389	CcSEcCtD
Lansoprazole—Visual impairment—Methotrexate—multiple sclerosis	8.82e-05	0.000389	CcSEcCtD
Lansoprazole—Anaemia—Prednisone—multiple sclerosis	8.81e-05	0.000388	CcSEcCtD
Lansoprazole—Shock—Dexamethasone—multiple sclerosis	8.79e-05	0.000387	CcSEcCtD
Lansoprazole—Shock—Betamethasone—multiple sclerosis	8.79e-05	0.000387	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	8.79e-05	0.0012	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TNF—multiple sclerosis	8.78e-05	0.0012	CbGpPWpGaD
Lansoprazole—Dyspnoea—Triamcinolone—multiple sclerosis	8.78e-05	0.000387	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	8.77e-05	0.0012	CbGpPWpGaD
Lansoprazole—Nervous system disorder—Dexamethasone—multiple sclerosis	8.76e-05	0.000386	CcSEcCtD
Lansoprazole—Nervous system disorder—Betamethasone—multiple sclerosis	8.76e-05	0.000386	CcSEcCtD
Lansoprazole—Agitation—Prednisone—multiple sclerosis	8.76e-05	0.000386	CcSEcCtD
Lansoprazole—Thrombocytopenia—Dexamethasone—multiple sclerosis	8.75e-05	0.000386	CcSEcCtD
Lansoprazole—Thrombocytopenia—Betamethasone—multiple sclerosis	8.75e-05	0.000386	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—SRM—multiple sclerosis	8.74e-05	0.0012	CbGpPWpGaD
Lansoprazole—Tachycardia—Dexamethasone—multiple sclerosis	8.72e-05	0.000384	CcSEcCtD
Lansoprazole—Tachycardia—Betamethasone—multiple sclerosis	8.72e-05	0.000384	CcSEcCtD
Lansoprazole—Angioedema—Prednisone—multiple sclerosis	8.71e-05	0.000384	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—ALB—multiple sclerosis	8.69e-05	0.00119	CbGpPWpGaD
Lansoprazole—Dyspepsia—Triamcinolone—multiple sclerosis	8.67e-05	0.000382	CcSEcCtD
Lansoprazole—Erythema multiforme—Methotrexate—multiple sclerosis	8.66e-05	0.000381	CcSEcCtD
Lansoprazole—Dyspepsia—Methylprednisolone—multiple sclerosis	8.65e-05	0.000381	CcSEcCtD
Lansoprazole—Hyperhidrosis—Betamethasone—multiple sclerosis	8.64e-05	0.000381	CcSEcCtD
Lansoprazole—Hyperhidrosis—Dexamethasone—multiple sclerosis	8.64e-05	0.000381	CcSEcCtD
Lansoprazole—Malaise—Prednisone—multiple sclerosis	8.6e-05	0.000379	CcSEcCtD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	8.57e-05	0.00117	CbGpPWpGaD
Lansoprazole—Vertigo—Prednisone—multiple sclerosis	8.57e-05	0.000377	CcSEcCtD
Lansoprazole—Eye disorder—Methotrexate—multiple sclerosis	8.56e-05	0.000377	CcSEcCtD
Lansoprazole—Syncope—Prednisone—multiple sclerosis	8.55e-05	0.000377	CcSEcCtD
Lansoprazole—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.54e-05	0.00117	CbGpPWpGaD
Lansoprazole—Tinnitus—Methotrexate—multiple sclerosis	8.54e-05	0.000376	CcSEcCtD
Lansoprazole—Anorexia—Betamethasone—multiple sclerosis	8.52e-05	0.000375	CcSEcCtD
Lansoprazole—Anorexia—Dexamethasone—multiple sclerosis	8.52e-05	0.000375	CcSEcCtD
Lansoprazole—Urticaria—Prednisolone—multiple sclerosis	8.51e-05	0.000375	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	8.51e-05	0.00117	CbGpPWpGaD
Lansoprazole—Cardiac disorder—Methotrexate—multiple sclerosis	8.5e-05	0.000374	CcSEcCtD
Lansoprazole—Fatigue—Triamcinolone—multiple sclerosis	8.49e-05	0.000374	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	8.49e-05	0.00116	CbGpPWpGaD
Lansoprazole—Fatigue—Methylprednisolone—multiple sclerosis	8.47e-05	0.000373	CcSEcCtD
Lansoprazole—Pain—Triamcinolone—multiple sclerosis	8.42e-05	0.000371	CcSEcCtD
Lansoprazole—Loss of consciousness—Prednisone—multiple sclerosis	8.38e-05	0.000369	CcSEcCtD
Lansoprazole—Hypotension—Dexamethasone—multiple sclerosis	8.35e-05	0.000368	CcSEcCtD
Lansoprazole—Hypotension—Betamethasone—multiple sclerosis	8.35e-05	0.000368	CcSEcCtD
Lansoprazole—CYP2C8—brain—multiple sclerosis	8.35e-05	0.0114	CbGeAlD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	8.32e-05	0.00114	CbGpPWpGaD
Lansoprazole—Angiopathy—Methotrexate—multiple sclerosis	8.31e-05	0.000366	CcSEcCtD
Lansoprazole—Vomiting—Mitoxantrone—multiple sclerosis	8.3e-05	0.000366	CcSEcCtD
Lansoprazole—Immune system disorder—Methotrexate—multiple sclerosis	8.27e-05	0.000364	CcSEcCtD
Lansoprazole—Convulsion—Prednisone—multiple sclerosis	8.26e-05	0.000364	CcSEcCtD
Lansoprazole—Mediastinal disorder—Methotrexate—multiple sclerosis	8.25e-05	0.000364	CcSEcCtD
Lansoprazole—Hypertension—Prednisone—multiple sclerosis	8.23e-05	0.000363	CcSEcCtD
Lansoprazole—Rash—Mitoxantrone—multiple sclerosis	8.23e-05	0.000363	CcSEcCtD
Lansoprazole—Dermatitis—Mitoxantrone—multiple sclerosis	8.22e-05	0.000362	CcSEcCtD
Lansoprazole—Chills—Methotrexate—multiple sclerosis	8.22e-05	0.000362	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	8.2e-05	0.00112	CbGpPWpGaD
Lansoprazole—Headache—Mitoxantrone—multiple sclerosis	8.18e-05	0.00036	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	8.14e-05	0.000359	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	8.14e-05	0.000359	CcSEcCtD
Lansoprazole—Myalgia—Prednisone—multiple sclerosis	8.12e-05	0.000358	CcSEcCtD
Lansoprazole—Arthralgia—Prednisone—multiple sclerosis	8.12e-05	0.000358	CcSEcCtD
Lansoprazole—Feeling abnormal—Triamcinolone—multiple sclerosis	8.12e-05	0.000358	CcSEcCtD
Lansoprazole—ABCG2—brain—multiple sclerosis	8.11e-05	0.0111	CbGeAlD
Lansoprazole—CYP2C18—Biological oxidations—POMC—multiple sclerosis	8.1e-05	0.00111	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Methylprednisolone—multiple sclerosis	8.1e-05	0.000357	CcSEcCtD
Lansoprazole—Anxiety—Prednisone—multiple sclerosis	8.09e-05	0.000356	CcSEcCtD
Lansoprazole—Alopecia—Methotrexate—multiple sclerosis	8.09e-05	0.000356	CcSEcCtD
Lansoprazole—Insomnia—Dexamethasone—multiple sclerosis	8.08e-05	0.000356	CcSEcCtD
Lansoprazole—Insomnia—Betamethasone—multiple sclerosis	8.08e-05	0.000356	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	8.06e-05	0.000355	CcSEcCtD
Lansoprazole—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.04e-05	0.0011	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.04e-05	0.0011	CbGpPWpGaD
Lansoprazole—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	8.04e-05	0.000354	CcSEcCtD
Lansoprazole—Paraesthesia—Betamethasone—multiple sclerosis	8.03e-05	0.000354	CcSEcCtD
Lansoprazole—Paraesthesia—Dexamethasone—multiple sclerosis	8.03e-05	0.000354	CcSEcCtD
Lansoprazole—Discomfort—Prednisone—multiple sclerosis	8.02e-05	0.000353	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—multiple sclerosis	8.02e-05	0.000353	CcSEcCtD
Lansoprazole—Malnutrition—Methotrexate—multiple sclerosis	7.97e-05	0.000351	CcSEcCtD
Lansoprazole—Erythema—Methotrexate—multiple sclerosis	7.97e-05	0.000351	CcSEcCtD
Lansoprazole—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.93e-05	0.00109	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.93e-05	0.00109	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	7.93e-05	0.00109	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—CD86—multiple sclerosis	7.9e-05	0.00108	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Prednisolone—multiple sclerosis	7.89e-05	0.000348	CcSEcCtD
Lansoprazole—Dyspepsia—Betamethasone—multiple sclerosis	7.87e-05	0.000347	CcSEcCtD
Lansoprazole—Dyspepsia—Dexamethasone—multiple sclerosis	7.87e-05	0.000347	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	7.84e-05	0.00107	CbGpPWpGaD
Lansoprazole—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.83e-05	0.00107	CbGpPWpGaD
Lansoprazole—Urticaria—Triamcinolone—multiple sclerosis	7.83e-05	0.000345	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	7.81e-05	0.00107	CbGpPWpGaD
Lansoprazole—Urticaria—Methylprednisolone—multiple sclerosis	7.81e-05	0.000344	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—multiple sclerosis	7.81e-05	0.000344	CcSEcCtD
Lansoprazole—Body temperature increased—Triamcinolone—multiple sclerosis	7.79e-05	0.000343	CcSEcCtD
Lansoprazole—Anaphylactic shock—Prednisone—multiple sclerosis	7.78e-05	0.000343	CcSEcCtD
Lansoprazole—Oedema—Prednisone—multiple sclerosis	7.78e-05	0.000343	CcSEcCtD
Lansoprazole—Abdominal pain—Methylprednisolone—multiple sclerosis	7.77e-05	0.000342	CcSEcCtD
Lansoprazole—Decreased appetite—Dexamethasone—multiple sclerosis	7.77e-05	0.000342	CcSEcCtD
Lansoprazole—Decreased appetite—Betamethasone—multiple sclerosis	7.77e-05	0.000342	CcSEcCtD
Lansoprazole—Nausea—Mitoxantrone—multiple sclerosis	7.76e-05	0.000342	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.75e-05	0.00106	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	7.74e-05	0.00106	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL10—multiple sclerosis	7.74e-05	0.00106	CbGpPWpGaD
Lansoprazole—Infection—Prednisone—multiple sclerosis	7.73e-05	0.000341	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Betamethasone—multiple sclerosis	7.72e-05	0.00034	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	7.72e-05	0.00034	CcSEcCtD
Lansoprazole—Back pain—Methotrexate—multiple sclerosis	7.71e-05	0.00034	CcSEcCtD
Lansoprazole—Fatigue—Betamethasone—multiple sclerosis	7.71e-05	0.000339	CcSEcCtD
Lansoprazole—Fatigue—Dexamethasone—multiple sclerosis	7.71e-05	0.000339	CcSEcCtD
Lansoprazole—CYP1A1—brain—multiple sclerosis	7.7e-05	0.0105	CbGeAlD
Lansoprazole—Shock—Prednisone—multiple sclerosis	7.66e-05	0.000337	CcSEcCtD
Lansoprazole—Pain—Dexamethasone—multiple sclerosis	7.64e-05	0.000337	CcSEcCtD
Lansoprazole—Pain—Betamethasone—multiple sclerosis	7.64e-05	0.000337	CcSEcCtD
Lansoprazole—Nervous system disorder—Prednisone—multiple sclerosis	7.63e-05	0.000336	CcSEcCtD
Lansoprazole—Tachycardia—Prednisone—multiple sclerosis	7.6e-05	0.000335	CcSEcCtD
Lansoprazole—Skin disorder—Prednisone—multiple sclerosis	7.56e-05	0.000333	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—IL4—multiple sclerosis	7.53e-05	0.00103	CbGpPWpGaD
Lansoprazole—Hyperhidrosis—Prednisone—multiple sclerosis	7.52e-05	0.000331	CcSEcCtD
Lansoprazole—Vision blurred—Methotrexate—multiple sclerosis	7.51e-05	0.000331	CcSEcCtD
Lansoprazole—Anorexia—Prednisone—multiple sclerosis	7.42e-05	0.000327	CcSEcCtD
Lansoprazole—Ill-defined disorder—Methotrexate—multiple sclerosis	7.4e-05	0.000326	CcSEcCtD
Lansoprazole—CYP3A4—nervous system—multiple sclerosis	7.4e-05	0.0101	CbGeAlD
Lansoprazole—Anaemia—Methotrexate—multiple sclerosis	7.37e-05	0.000325	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	7.37e-05	0.00101	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Dexamethasone—multiple sclerosis	7.37e-05	0.000324	CcSEcCtD
Lansoprazole—Feeling abnormal—Betamethasone—multiple sclerosis	7.37e-05	0.000324	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Betamethasone—multiple sclerosis	7.31e-05	0.000322	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Dexamethasone—multiple sclerosis	7.31e-05	0.000322	CcSEcCtD
Lansoprazole—CYP2D6—nervous system—multiple sclerosis	7.28e-05	0.00995	CbGeAlD
Lansoprazole—Hypersensitivity—Triamcinolone—multiple sclerosis	7.26e-05	0.00032	CcSEcCtD
Lansoprazole—Hypersensitivity—Methylprednisolone—multiple sclerosis	7.24e-05	0.000319	CcSEcCtD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	7.19e-05	0.000985	CbGpPWpGaD
Lansoprazole—Malaise—Methotrexate—multiple sclerosis	7.19e-05	0.000317	CcSEcCtD
Lansoprazole—Vertigo—Methotrexate—multiple sclerosis	7.16e-05	0.000315	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—multiple sclerosis	7.13e-05	0.000314	CcSEcCtD
Lansoprazole—CYP3A4—central nervous system—multiple sclerosis	7.12e-05	0.00973	CbGeAlD
Lansoprazole—Urticaria—Dexamethasone—multiple sclerosis	7.1e-05	0.000313	CcSEcCtD
Lansoprazole—Urticaria—Betamethasone—multiple sclerosis	7.1e-05	0.000313	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Prednisone—multiple sclerosis	7.09e-05	0.000312	CcSEcCtD
Lansoprazole—Dizziness—Prednisolone—multiple sclerosis	7.08e-05	0.000312	CcSEcCtD
Lansoprazole—Asthenia—Triamcinolone—multiple sclerosis	7.07e-05	0.000311	CcSEcCtD
Lansoprazole—Body temperature increased—Betamethasone—multiple sclerosis	7.07e-05	0.000311	CcSEcCtD
Lansoprazole—Body temperature increased—Dexamethasone—multiple sclerosis	7.07e-05	0.000311	CcSEcCtD
Lansoprazole—Abdominal pain—Betamethasone—multiple sclerosis	7.07e-05	0.000311	CcSEcCtD
Lansoprazole—Abdominal pain—Dexamethasone—multiple sclerosis	7.07e-05	0.000311	CcSEcCtD
Lansoprazole—Asthenia—Methylprednisolone—multiple sclerosis	7.05e-05	0.000311	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—CYP24A1—multiple sclerosis	7.04e-05	0.000965	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CYP27B1—multiple sclerosis	7.04e-05	0.000965	CbGpPWpGaD
Lansoprazole—Insomnia—Prednisone—multiple sclerosis	7.04e-05	0.00031	CcSEcCtD
Lansoprazole—CYP2D6—central nervous system—multiple sclerosis	7.01e-05	0.00958	CbGeAlD
Lansoprazole—Paraesthesia—Prednisone—multiple sclerosis	6.99e-05	0.000308	CcSEcCtD
Lansoprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.99e-05	0.000957	CbGpPWpGaD
Lansoprazole—Pruritus—Triamcinolone—multiple sclerosis	6.97e-05	0.000307	CcSEcCtD
Lansoprazole—ABCB1—medulla oblongata—multiple sclerosis	6.97e-05	0.00952	CbGeAlD
Lansoprazole—Cough—Methotrexate—multiple sclerosis	6.96e-05	0.000306	CcSEcCtD
Lansoprazole—Pruritus—Methylprednisolone—multiple sclerosis	6.95e-05	0.000306	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—FAS—multiple sclerosis	6.94e-05	0.000951	CbGpPWpGaD
Lansoprazole—CYP1A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.92e-05	0.000949	CbGpPWpGaD
Lansoprazole—Convulsion—Methotrexate—multiple sclerosis	6.91e-05	0.000304	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	6.9e-05	0.000946	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.89e-05	0.000943	CbGpPWpGaD
Lansoprazole—Dyspepsia—Prednisone—multiple sclerosis	6.85e-05	0.000302	CcSEcCtD
Lansoprazole—CYP2D6—cerebellum—multiple sclerosis	6.85e-05	0.00936	CbGeAlD
Lansoprazole—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	6.82e-05	0.000935	CbGpPWpGaD
Lansoprazole—Chest pain—Methotrexate—multiple sclerosis	6.79e-05	0.000299	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—multiple sclerosis	6.79e-05	0.000299	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—multiple sclerosis	6.79e-05	0.000299	CcSEcCtD
Lansoprazole—Decreased appetite—Prednisone—multiple sclerosis	6.77e-05	0.000298	CcSEcCtD
Lansoprazole—Rash—Prednisolone—multiple sclerosis	6.75e-05	0.000298	CcSEcCtD
Lansoprazole—Dermatitis—Prednisolone—multiple sclerosis	6.75e-05	0.000297	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	6.74e-05	0.000297	CcSEcCtD
Lansoprazole—Diarrhoea—Methylprednisolone—multiple sclerosis	6.72e-05	0.000296	CcSEcCtD
Lansoprazole—Fatigue—Prednisone—multiple sclerosis	6.71e-05	0.000296	CcSEcCtD
Lansoprazole—Headache—Prednisolone—multiple sclerosis	6.71e-05	0.000296	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—multiple sclerosis	6.7e-05	0.000295	CcSEcCtD
Lansoprazole—Constipation—Prednisone—multiple sclerosis	6.66e-05	0.000293	CcSEcCtD
Lansoprazole—Confusional state—Methotrexate—multiple sclerosis	6.56e-05	0.000289	CcSEcCtD
Lansoprazole—Dizziness—Triamcinolone—multiple sclerosis	6.51e-05	0.000287	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—multiple sclerosis	6.5e-05	0.000287	CcSEcCtD
Lansoprazole—Dizziness—Methylprednisolone—multiple sclerosis	6.5e-05	0.000286	CcSEcCtD
Lansoprazole—Infection—Methotrexate—multiple sclerosis	6.46e-05	0.000285	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—GPC5—multiple sclerosis	6.44e-05	0.000883	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SRM—multiple sclerosis	6.44e-05	0.000883	CbGpPWpGaD
Lansoprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.43e-05	0.000881	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Prednisone—multiple sclerosis	6.41e-05	0.000283	CcSEcCtD
Lansoprazole—Asthenia—Dexamethasone—multiple sclerosis	6.41e-05	0.000282	CcSEcCtD
Lansoprazole—Asthenia—Betamethasone—multiple sclerosis	6.41e-05	0.000282	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—multiple sclerosis	6.38e-05	0.000281	CcSEcCtD
Lansoprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.37e-05	0.000873	CbGpPWpGaD
Lansoprazole—Thrombocytopenia—Methotrexate—multiple sclerosis	6.37e-05	0.000281	CcSEcCtD
Lansoprazole—ABCB1—midbrain—multiple sclerosis	6.37e-05	0.0087	CbGeAlD
Lansoprazole—Gastrointestinal pain—Prednisone—multiple sclerosis	6.36e-05	0.00028	CcSEcCtD
Lansoprazole—Nausea—Prednisolone—multiple sclerosis	6.36e-05	0.00028	CcSEcCtD
Lansoprazole—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.35e-05	0.00087	CbGpPWpGaD
Lansoprazole—Pruritus—Dexamethasone—multiple sclerosis	6.32e-05	0.000279	CcSEcCtD
Lansoprazole—Pruritus—Betamethasone—multiple sclerosis	6.32e-05	0.000279	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—multiple sclerosis	6.32e-05	0.000278	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—multiple sclerosis	6.29e-05	0.000277	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.28e-05	0.00086	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.28e-05	0.00086	CbGpPWpGaD
Lansoprazole—Vomiting—Triamcinolone—multiple sclerosis	6.26e-05	0.000276	CcSEcCtD
Lansoprazole—Vomiting—Methylprednisolone—multiple sclerosis	6.25e-05	0.000275	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	6.23e-05	0.000854	CbGpPWpGaD
Lansoprazole—ABCB1—spinal cord—multiple sclerosis	6.21e-05	0.00849	CbGeAlD
Lansoprazole—Rash—Triamcinolone—multiple sclerosis	6.21e-05	0.000274	CcSEcCtD
Lansoprazole—Dermatitis—Triamcinolone—multiple sclerosis	6.21e-05	0.000273	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—multiple sclerosis	6.2e-05	0.000273	CcSEcCtD
Lansoprazole—Rash—Methylprednisolone—multiple sclerosis	6.2e-05	0.000273	CcSEcCtD
Lansoprazole—Dermatitis—Methylprednisolone—multiple sclerosis	6.19e-05	0.000273	CcSEcCtD
Lansoprazole—Urticaria—Prednisone—multiple sclerosis	6.18e-05	0.000272	CcSEcCtD
Lansoprazole—Headache—Triamcinolone—multiple sclerosis	6.17e-05	0.000272	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—CYP24A1—multiple sclerosis	6.16e-05	0.000844	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CYP27B1—multiple sclerosis	6.16e-05	0.000844	CbGpPWpGaD
Lansoprazole—Headache—Methylprednisolone—multiple sclerosis	6.16e-05	0.000271	CcSEcCtD
Lansoprazole—Abdominal pain—Prednisone—multiple sclerosis	6.15e-05	0.000271	CcSEcCtD
Lansoprazole—Body temperature increased—Prednisone—multiple sclerosis	6.15e-05	0.000271	CcSEcCtD
Lansoprazole—Diarrhoea—Dexamethasone—multiple sclerosis	6.12e-05	0.000269	CcSEcCtD
Lansoprazole—Diarrhoea—Betamethasone—multiple sclerosis	6.12e-05	0.000269	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	6.11e-05	0.000837	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—TGFB1—multiple sclerosis	6.09e-05	0.000835	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	6.09e-05	0.000835	CbGpPWpGaD
Lansoprazole—Hypotension—Methotrexate—multiple sclerosis	6.08e-05	0.000268	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	5.97e-05	0.000818	CbGpPWpGaD
Lansoprazole—CYP1B1—Biological oxidations—POMC—multiple sclerosis	5.97e-05	0.000818	CbGpPWpGaD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.93e-05	0.000261	CcSEcCtD
Lansoprazole—Dizziness—Dexamethasone—multiple sclerosis	5.91e-05	0.00026	CcSEcCtD
Lansoprazole—Dizziness—Betamethasone—multiple sclerosis	5.91e-05	0.00026	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—multiple sclerosis	5.88e-05	0.000259	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—SRM—multiple sclerosis	5.86e-05	0.000803	CbGpPWpGaD
Lansoprazole—Nausea—Triamcinolone—multiple sclerosis	5.85e-05	0.000258	CcSEcCtD
Lansoprazole—Paraesthesia—Methotrexate—multiple sclerosis	5.84e-05	0.000257	CcSEcCtD
Lansoprazole—Nausea—Methylprednisolone—multiple sclerosis	5.84e-05	0.000257	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—multiple sclerosis	5.8e-05	0.000255	CcSEcCtD
Lansoprazole—Somnolence—Methotrexate—multiple sclerosis	5.78e-05	0.000255	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—CD80—multiple sclerosis	5.76e-05	0.000789	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.75e-05	0.000789	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.75e-05	0.000789	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Prednisone—multiple sclerosis	5.73e-05	0.000253	CcSEcCtD
Lansoprazole—Dyspepsia—Methotrexate—multiple sclerosis	5.73e-05	0.000252	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	5.69e-05	0.000779	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	5.69e-05	0.000779	CbGpPWpGaD
Lansoprazole—Vomiting—Dexamethasone—multiple sclerosis	5.68e-05	0.00025	CcSEcCtD
Lansoprazole—Vomiting—Betamethasone—multiple sclerosis	5.68e-05	0.00025	CcSEcCtD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	5.68e-05	0.000779	CbGpPWpGaD
Lansoprazole—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.66e-05	0.000776	CbGpPWpGaD
Lansoprazole—Decreased appetite—Methotrexate—multiple sclerosis	5.65e-05	0.000249	CcSEcCtD
Lansoprazole—Rash—Betamethasone—multiple sclerosis	5.64e-05	0.000248	CcSEcCtD
Lansoprazole—Rash—Dexamethasone—multiple sclerosis	5.64e-05	0.000248	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—GPC5—multiple sclerosis	5.63e-05	0.000772	CbGpPWpGaD
Lansoprazole—Dermatitis—Betamethasone—multiple sclerosis	5.63e-05	0.000248	CcSEcCtD
Lansoprazole—Dermatitis—Dexamethasone—multiple sclerosis	5.63e-05	0.000248	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—multiple sclerosis	5.62e-05	0.000247	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—multiple sclerosis	5.61e-05	0.000247	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	5.6e-05	0.000768	CbGpPWpGaD
Lansoprazole—Headache—Dexamethasone—multiple sclerosis	5.6e-05	0.000247	CcSEcCtD
Lansoprazole—Headache—Betamethasone—multiple sclerosis	5.6e-05	0.000247	CcSEcCtD
Lansoprazole—Asthenia—Prednisone—multiple sclerosis	5.58e-05	0.000246	CcSEcCtD
Lansoprazole—Pain—Methotrexate—multiple sclerosis	5.56e-05	0.000245	CcSEcCtD
Lansoprazole—CYP2D6—brain—multiple sclerosis	5.56e-05	0.0076	CbGeAlD
Lansoprazole—Pruritus—Prednisone—multiple sclerosis	5.51e-05	0.000243	CcSEcCtD
Lansoprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.44e-05	0.000746	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Methotrexate—multiple sclerosis	5.36e-05	0.000236	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—RRM1—multiple sclerosis	5.34e-05	0.000732	CbGpPWpGaD
Lansoprazole—Diarrhoea—Prednisone—multiple sclerosis	5.33e-05	0.000235	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—multiple sclerosis	5.32e-05	0.000234	CcSEcCtD
Lansoprazole—Nausea—Betamethasone—multiple sclerosis	5.31e-05	0.000234	CcSEcCtD
Lansoprazole—Nausea—Dexamethasone—multiple sclerosis	5.31e-05	0.000234	CcSEcCtD
Lansoprazole—ABCB1—nervous system—multiple sclerosis	5.23e-05	0.00715	CbGeAlD
Lansoprazole—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.21e-05	0.000714	CbGpPWpGaD
Lansoprazole—Urticaria—Methotrexate—multiple sclerosis	5.17e-05	0.000228	CcSEcCtD
Lansoprazole—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.17e-05	0.000708	CbGpPWpGaD
Lansoprazole—Dizziness—Prednisone—multiple sclerosis	5.15e-05	0.000227	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—multiple sclerosis	5.14e-05	0.000227	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—multiple sclerosis	5.14e-05	0.000227	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.14e-05	0.000704	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.14e-05	0.000704	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.13e-05	0.000703	CbGpPWpGaD
Lansoprazole—ABCB1—central nervous system—multiple sclerosis	5.04e-05	0.00689	CbGeAlD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.02e-05	0.000688	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	5e-05	0.000685	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	4.99e-05	0.000683	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	4.98e-05	0.000682	CbGpPWpGaD
Lansoprazole—Vomiting—Prednisone—multiple sclerosis	4.95e-05	0.000218	CcSEcCtD
Lansoprazole—ABCB1—cerebellum—multiple sclerosis	4.93e-05	0.00673	CbGeAlD
Lansoprazole—Rash—Prednisone—multiple sclerosis	4.91e-05	0.000216	CcSEcCtD
Lansoprazole—Dermatitis—Prednisone—multiple sclerosis	4.9e-05	0.000216	CcSEcCtD
Lansoprazole—Headache—Prednisone—multiple sclerosis	4.88e-05	0.000215	CcSEcCtD
Lansoprazole—Hypersensitivity—Methotrexate—multiple sclerosis	4.79e-05	0.000211	CcSEcCtD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.68e-05	0.000642	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.68e-05	0.000642	CbGpPWpGaD
Lansoprazole—Asthenia—Methotrexate—multiple sclerosis	4.67e-05	0.000206	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—RRM1—multiple sclerosis	4.67e-05	0.000639	CbGpPWpGaD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	4.64e-05	0.000635	CbGpPWpGaD
Lansoprazole—Nausea—Prednisone—multiple sclerosis	4.62e-05	0.000204	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—multiple sclerosis	4.6e-05	0.000203	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	4.55e-05	0.000624	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CYP27B1—multiple sclerosis	4.54e-05	0.000622	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CYP24A1—multiple sclerosis	4.54e-05	0.000622	CbGpPWpGaD
Lansoprazole—Diarrhoea—Methotrexate—multiple sclerosis	4.45e-05	0.000196	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.44e-05	0.000608	CbGpPWpGaD
Lansoprazole—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.41e-05	0.000605	CbGpPWpGaD
Lansoprazole—Dizziness—Methotrexate—multiple sclerosis	4.3e-05	0.00019	CcSEcCtD
Lansoprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.2e-05	0.000576	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GPC5—multiple sclerosis	4.15e-05	0.000569	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.14e-05	0.000568	CbGpPWpGaD
Lansoprazole—Vomiting—Methotrexate—multiple sclerosis	4.14e-05	0.000182	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—CYP27B1—multiple sclerosis	4.13e-05	0.000566	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP24A1—multiple sclerosis	4.13e-05	0.000566	CbGpPWpGaD
Lansoprazole—Rash—Methotrexate—multiple sclerosis	4.1e-05	0.000181	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—multiple sclerosis	4.1e-05	0.000181	CcSEcCtD
Lansoprazole—Headache—Methotrexate—multiple sclerosis	4.08e-05	0.00018	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	4.06e-05	0.000557	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL2—multiple sclerosis	4.05e-05	0.000554	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4e-05	0.000548	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4e-05	0.000548	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4e-05	0.000548	CbGpPWpGaD
Lansoprazole—ABCB1—brain—multiple sclerosis	4e-05	0.00547	CbGeAlD
Lansoprazole—CYP1A1—Metabolism—SRM—multiple sclerosis	3.97e-05	0.000544	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	3.89e-05	0.000533	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.89e-05	0.000533	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	3.88e-05	0.000532	CbGpPWpGaD
Lansoprazole—Nausea—Methotrexate—multiple sclerosis	3.86e-05	0.00017	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	3.81e-05	0.000522	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GPC5—multiple sclerosis	3.78e-05	0.000518	CbGpPWpGaD
Lansoprazole—CYP1A1—Biological oxidations—POMC—multiple sclerosis	3.68e-05	0.000504	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SRM—multiple sclerosis	3.64e-05	0.000498	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	3.63e-05	0.000497	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	3.63e-05	0.000497	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.56e-05	0.000488	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—RRM1—multiple sclerosis	3.44e-05	0.000471	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.43e-05	0.000469	CbGpPWpGaD
Lansoprazole—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.41e-05	0.000467	CbGpPWpGaD
Lansoprazole—CYP2C8—Biological oxidations—POMC—multiple sclerosis	3.37e-05	0.000462	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SRM—multiple sclerosis	3.25e-05	0.000445	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.24e-05	0.000445	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SRM—multiple sclerosis	3.17e-05	0.000434	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.16e-05	0.000432	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—RRM1—multiple sclerosis	3.13e-05	0.000429	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.07e-05	0.000421	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—BCHE—multiple sclerosis	3.07e-05	0.00042	CbGpPWpGaD
Lansoprazole—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.01e-05	0.000412	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SRM—multiple sclerosis	2.99e-05	0.000409	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SRM—multiple sclerosis	2.96e-05	0.000406	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.95e-05	0.000404	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	2.8e-05	0.000383	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	2.8e-05	0.000383	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.77e-05	0.000379	CbGpPWpGaD
Lansoprazole—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.74e-05	0.000376	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.73e-05	0.000374	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.72e-05	0.000372	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—BCHE—multiple sclerosis	2.68e-05	0.000367	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.67e-05	0.000366	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	2.56e-05	0.000351	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	2.56e-05	0.000351	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GPC5—multiple sclerosis	2.56e-05	0.00035	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SRM—multiple sclerosis	2.53e-05	0.000347	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.5e-05	0.000343	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.34e-05	0.000321	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GPC5—multiple sclerosis	2.34e-05	0.000321	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.29e-05	0.000314	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.29e-05	0.000313	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.29e-05	0.000313	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.24e-05	0.000306	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.23e-05	0.000306	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.23e-05	0.000306	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—RRM1—multiple sclerosis	2.12e-05	0.00029	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.1e-05	0.000288	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.1e-05	0.000288	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.09e-05	0.000287	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.09e-05	0.000286	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.09e-05	0.000286	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.09e-05	0.000286	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GPC5—multiple sclerosis	2.04e-05	0.00028	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.04e-05	0.000279	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—BCHE—multiple sclerosis	1.98e-05	0.000271	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SRM—multiple sclerosis	1.95e-05	0.000268	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—RRM1—multiple sclerosis	1.94e-05	0.000266	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.92e-05	0.000264	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.91e-05	0.000261	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—APOE—multiple sclerosis	1.84e-05	0.000253	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.81e-05	0.000248	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.81e-05	0.000248	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—BCHE—multiple sclerosis	1.8e-05	0.000246	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.78e-05	0.000244	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.78e-05	0.000244	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.74e-05	0.000239	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.73e-05	0.000238	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—RRM1—multiple sclerosis	1.69e-05	0.000232	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.64e-05	0.000225	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.63e-05	0.000223	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—APOE—multiple sclerosis	1.61e-05	0.000221	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.59e-05	0.000218	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—POMC—multiple sclerosis	1.58e-05	0.000217	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.58e-05	0.000217	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.56e-05	0.000214	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.56e-05	0.000213	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.53e-05	0.000209	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.51e-05	0.000206	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.45e-05	0.000199	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ALB—multiple sclerosis	1.44e-05	0.000198	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.41e-05	0.000193	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—POMC—multiple sclerosis	1.39e-05	0.00019	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.38e-05	0.000188	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.38e-05	0.000188	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.35e-05	0.000185	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.35e-05	0.000184	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.29e-05	0.000177	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.29e-05	0.000176	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ALB—multiple sclerosis	1.26e-05	0.000173	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.26e-05	0.000172	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.23e-05	0.000168	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—BCHE—multiple sclerosis	1.22e-05	0.000167	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—APOE—multiple sclerosis	1.19e-05	0.000163	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.18e-05	0.000162	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.16e-05	0.000158	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.12e-05	0.000153	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—APOE—multiple sclerosis	1.08e-05	0.000148	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.04e-05	0.000143	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—POMC—multiple sclerosis	1.02e-05	0.00014	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—BCHE—multiple sclerosis	9.96e-06	0.000136	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.78e-06	0.000134	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—BCHE—multiple sclerosis	9.72e-06	0.000133	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.61e-06	0.000132	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ALB—multiple sclerosis	9.31e-06	0.000128	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—POMC—multiple sclerosis	9.29e-06	0.000127	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—BCHE—multiple sclerosis	9.16e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.08e-06	0.000124	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9e-06	0.000123	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ALB—multiple sclerosis	8.47e-06	0.000116	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.21e-06	0.000112	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—BCHE—multiple sclerosis	7.76e-06	0.000106	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—APOE—multiple sclerosis	7.32e-06	0.0001	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—APOE—multiple sclerosis	6.71e-06	9.2e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—POMC—multiple sclerosis	6.29e-06	8.62e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—APOE—multiple sclerosis	5.99e-06	8.21e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—BCHE—multiple sclerosis	5.99e-06	8.2e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—APOE—multiple sclerosis	5.85e-06	8.01e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—POMC—multiple sclerosis	5.77e-06	7.9e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ALB—multiple sclerosis	5.73e-06	7.86e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—APOE—multiple sclerosis	5.51e-06	7.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—APOE—multiple sclerosis	5.46e-06	7.48e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ALB—multiple sclerosis	5.26e-06	7.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—POMC—multiple sclerosis	5.15e-06	7.05e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—POMC—multiple sclerosis	5.02e-06	6.88e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—POMC—multiple sclerosis	4.73e-06	6.49e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—POMC—multiple sclerosis	4.69e-06	6.43e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ALB—multiple sclerosis	4.69e-06	6.43e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—APOE—multiple sclerosis	4.67e-06	6.4e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ALB—multiple sclerosis	4.58e-06	6.27e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALB—multiple sclerosis	4.32e-06	5.91e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALB—multiple sclerosis	4.28e-06	5.86e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—POMC—multiple sclerosis	4.01e-06	5.49e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALB—multiple sclerosis	3.66e-06	5.01e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—APOE—multiple sclerosis	3.6e-06	4.94e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—POMC—multiple sclerosis	3.09e-06	4.24e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALB—multiple sclerosis	2.82e-06	3.87e-05	CbGpPWpGaD
